Special Issue "Recent Advances in Vulvar Cancer"
Deadline for manuscript submissions: closed (15 November 2021) | Viewed by 53114
Interests: vulvar intraepithelial neoplasia; vulvar cancer; cervical cancer screening; HPV
2. Department of Obstetrics and Gynecology, University Hospital of Strasbourg, 67091 Strasbourg, France
Interests: gynecologic oncology; quality assurance; guidelines; laparoscopic surgery
Even though Vulvar Squamous Cell Carcinoma (VSCC) is a rare malignancy, representing 4% of all gynecological cancers, its incidence has been progressively increasing over the last few decades, particularly in women aged 50–60 years. Moreover, its incidence has increased in older patients, and no significant improvements in outcomes have been reported in decades.
At least two main pathways have been identified in VSCC oncogenesis. The first, which is more commonly found in younger women, has high-grade vulvar squamous intraepithelial neoplasia as a precursor and HPV infection in over 80% of cases. The second pathway arises within chronic dermatoses as lichen sclerosus and lichen planus, typical of older women, with differentiated VIN (dVIN) considered to be a transient pre-invasive lesion that rapidly progresses to an invasive malignancy. In addition, genomic alterations have different pathways, with p53 and HPV status having both prognostic and predictive value. Recently, researchers have identified a third subgroup with normal p53 expression, NOTCH1 and HRAS mutations (HPVneg/TP53wt VSCC), and an intermediate 5-year survival rate.
This Special Issue will focus on VSCC oncogenesis, its clinical and histopathological diagnosis, multimodal therapeutic approaches, adjuvant treatment, and tailored follow-up with psycho-sexuological support. The latest developments in the field of VSCC research, ranging from the tumor’s immune microenvironment to potential new approaches in advanced cases, will also be discussed.
Prof. Mario Preti
Prof. Denis Querleu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vulvar cancer
- genomic alteration
- sentinel node
- recurrent disease
- quality of life